Gout Prevention Project. Simplifying Gout Prevention Management for GPs and Patients
|
|
- Helena Bryan
- 6 years ago
- Views:
Transcription
1 Gout Prevention Project Simplifying Gout Prevention Management for GPs and Patients
2 Gout Prevalance 2
3 Gout Management primary care level 52.8% of PCP provided optimal medication treatment for acute attack 3.4% of PCPs would appropriately treat inter-critical gout in the setting of CKD 16.7% provided optimal care for chronic tophaceous gout Primary Care and ER Physicians are first line for acute gouty attacks 3 Harrold LR, et al. Rheumatology, 2013.
4 Objective of the Project This open evaluation had the following objectives: To evaluate the treatment of acute gout and the initiation of preventative treatment in a selected group of patients according to a specific treatment regime referred to as the Gout Starter Pack. To assess the process of providing medication according to a prescription written for a Gout Starter Pack and patient adherence to this regimen.
5 Evaluation Population Inclusion Criteria: Clinical diagnosis of acute gout attack Vital signs within range (Temperature<37 0 C, BP systolic >100 mmhg, Pulse<100 beats/minute) Patient can move joint in spite of pain Attacks 2 per annum Exclusion criteria: (Refer to Rheumatologist) Doubt about diagnosis Septic Arthritis Avoid treatment with colchicine if egfr very low
6 Evaluation Criteria Clinical condition of patient: Tolerance of allopurinol treatment Resolution of gout Serum uric acid levels monitored as follows: In the last week of Gout Starter Pack regimen (day 85 91) Patient education and adherence: Patient understanding of treatment necessary for acute gout attack Patient understanding of need for allopurinol on long-term basis. Treatment success was based on: Serum uric acid levels 0.36 mmol/l Patient on a maintenance dose of allopurinol.
7 In a nutshell Set up Acute Gout Starter Packs in Rx One script covers the acute attack and up titration over next 3 months At presentation the pharmacist is given a lab form for check UA at end of last pack Over this time the patient is seen 4 times by the pharmacist and has Arthritis NZ Gout Educator contact the patient The results of this process are encouraging
8
9
10
11 Acute Gout Starter Packs GOUT STARTER PACK egfr > 60 Sig: Prednisone 40mg 4/7, 20mg 4/7, 10mg 3/7, 5mg 3/7. Colchicine 500mcg bd 3/12. Allopurinol 100mg daily 1/12, 200mg daily 1/12, 300mg daily 1/12. Mitte: 1 GOUT STARTER PACK egfr Sig: Prednisone 40mg 4/7, 20mg 4/7, 10mg 3/7, 5mg 3/7. Colchicine 500mcg once daily 3/12. Allopurinol 50mg daily 1/12, 50mg daily 1/12,100mg daily 1/12. Mitte: 1 GOUT STARTER PACK egfr < 30 Sig: Prednisone 40mg 4/7, 20mg 4/7, 10mg 3/7, 5mg 3/7. Colchicine 500mcg every other day 3/12. Allopurinol 50mg every other day 1/12, 50mg every other day 1/12, 100mg daily 1/12. Mitte: 1
12
13
14 Interim Results Overall group n=20 Completed n=14 Success n = 9 Titration n = 5 Withdrawn n=4 On-going n = 2 Age (years) Mean Range Gender Male Female 15 (75%) 5 (25%) 10 (71.4%) 4 (28.6%) 7 (77.8%) 2 (22.2%) 3 (60%) 2 (40%) 3 (75%) 1 (25%) 2 (100%) Ethnicity NZ Maori NZ European European
15 Patients Requiring Up Titration Patient No Age (yrs) Gender M M F M F Ethnicity European NZ Maori NZ European NZ European NZ European Treatment Option Serum uric acid level Day 0 Day Uric acid level change Any intolerance to medication No No No No No Treatment Success No Titration No Titration No Titration No Titration No Titration Comments Rx: Allopurinol 150mg daily Colchicine Rx; Allopurinol 400mg daily Colchicine Rx; Allopurinol 200mg daily Colchicine Rx; Allopurinol 400mg daily Colchicine Rx; Allopurinol 200mg daily Colchicine
16 Patients Withdrawn from Patient No 6 Evaluation Age (yrs) Gender M M M F Ethinicity NZ Maori NZ European NZ European NZ Maori Treatment Option Blister pack 1 Stopped - blood glucose rising Collected Only 6 days Collected Blister pack 2 Collected Collected Collected Patient declined Blister pack 3 Collected late Collected - - Blister pack 4 Rx Did not collect Patient hospitalized - - Uric acid level Drop to 0.29 Any intolerance to medication Yes Prednisone No Yes -Prednisone keeps patient awake Nil of note
17
18 Amended Starter Packs GOUT STARTER PACK egfr > 60 Sig: Prednisone 40mg 4/7, 20mg 4/7, 10mg 3/7, 5mg 3/7. Colchicine 500mcg bd 3/12. Allopurinol 100mg daily 1/12, 200mg daily 1/12, 300mg daily 1/12. Mitte: 1 GOUT STARTER PACK egfr Sig: Prednisone 40mg 4/7, 20mg 4/7, 10mg 3/7, 5mg 3/7. Colchicine 500mcg once daily 3/12. Allopurinol 50mg daily 1/12, 100mg daily 1/12,150mg daily 1/12. Mitte: 1 GOUT STARTER PACK egfr < 30 Sig: Prednisone 40mg 4/7, 20mg 4/7, 10mg 3/7, 5mg 3/7. Colchicine 500mcg every other day 3/12. Allopurinol 50mg every other day 1/12, 50mg daily 1/12, 100 mg daily 1/12. Mitte: 1
19 Simple Messages 1.Gout is not only a pain in your toe; it's a WAKE UP call to take care of your heart, health and wellbeing. 2.Gout is not cured, even when the pain goes away, but lifestyle changes and medication such as allopurinol can stop gout's bad effects by hitting the target - uric acid less than Your genes play an important part in gout, it is not just your diet
20 Rheumatologist Message Doses above recommended dose are effective for lowering sua with few adverse events Patients with renal impairment tolerated allopurinol doses higher than CrCl-based doses and achieved sua <0.36 Monitor sua regularly and treat-to-target sua <0.36 Stamp LK, et al. Arthritis Rheum
Gout: Update in therapeutics
Summary Gout: Update in therapeutics 29/11/14 Caroline van Durme CHU de Liège Maastricht University Medical Centre+ Why treating gout? Guidelines: ACR 12 Drugs: Colchicine Allopurinol: what about the kidney?
More informationManagement of early chronic kidney disease
Management of early chronic kidney disease GREENLANE SUMMER GP SYMPOSIUM 2018 Jonathan Hsiao Renal and General Physician Introduction A growing public health problem in NZ and throughout the world. Unknown
More informationAcute hot swollen joint. Dr Edward Roddy Senior Lecturer in Rheumatology and Consultant Rheumatologist
Acute hot swollen joint Dr Edward Roddy Senior Lecturer in Rheumatology and Consultant Rheumatologist Acute monoarthritis: differential diagnosis Septic arthritis Crystal arthritis (gout, pseudogout) Haemarthrosis
More informationGout 2.0. Scott Vogelgesang, M.D. Division of Immunology: Rheumatology & Allergy
Gout 2.0 Scott Vogelgesang, M.D. Division of Immunology: Rheumatology & Allergy Case 48 year old man presents with swollen, painful left toe that started overnight. Didn t hurt when he went to bed. No
More informationOBJECTIVES GOUT GOUTY INFLAMMATION 6/10/2016 GOUT INCIDENCE AND PREVALENCE MONOSODIUM URATE CRYSTAL DEPOSITION DISEASE
GOUT Lisa Talbert, MD Family Medicine Update June 15, 2016 OBJECTIVES To be familiar with the clinical presentation and pathophysiology of gouty arthritis Be able to incorporate current guidelines when
More informationAn update on the management of gout
An update on the management of gout 8 The management of gout involves treatment of an acute attack, lifestyle modification and urate lowering treatment to achieve a target serum urate level. Recent evidence
More informationGout- Treatment Updates. Harinder Singh, MD Rheumatology Mercy Internal Medicine Clinic Mason City, IA
Gout- Treatment Updates Harinder Singh, MD Rheumatology Mercy Internal Medicine Clinic Mason City, IA Gout Outline of purine metabolism: (1) amidophosphoribosyltransferase (2) hypoxanthine-guanine phosphoribosyltransferase
More informationLowering serum urate levels in patients with gout
CLINICAL AUDIT Lowering serum urate levels in patients with gout Valid to April 2022 bpac nz better medicin e Background Gout, caused by increased levels of urate in the blood (hyperuricaemia), is the
More informationA Process for Performing Medication Assessments
A Process for Performing Medication Assessments Derek Jorgenson, BSP, PharmD, FCSHP College of Pharmacy and Nutrition University of Saskatchewan Objectives 1. Learn an overview of a medication assessment
More informationDr Daniel Ching. Rheumatology Therapeutic Clinical Trials Centre Timaru
Dr Daniel Ching Rheumatology Therapeutic Clinical Trials Centre Timaru Hot Tips in Rheumatology GP CME Meeting, Dunedin 17.08.2013 Dr Daniel Ching, MB FRCP FRACP Consultant Rheumatologist, Timaru Disclosures
More informationGout A rapid review. Jeremy Jones
Gout A rapid review Jeremy Jones The Hyperuricemia Cascade Dietary purines Tissue nucleic acids Urate Endogenous purine synthesis Overproduction Hyperuricemia Underexcretion Silent tissue deposition Gout
More informationWhat will happen in the future? How will gout be diagnosed? How is gout treated? prevent
Rheumatology Day Unit Dr J Hamilton 0191 4458359 0191 4455240 (9-5 Mon-Fri) Dr C Heycock 0191 4452198 Answer phone on 24hours Dr C Kelly 0191 4452193 Dr V Saravanan 0191 4456055 Dr M Rynne 0191 4458359
More informationGOUT. Dr Krishnan Baburaj West herts NHS Trust
GOUT Dr Krishnan Baburaj West herts NHS Trust podagra Gout A disease of kings, the king of diseases History Louis XIV Emperor Augustus Henry VIII Introduction Gout an inflammatory arthritic condition that
More informationGout -revisited. Shrenik Shah
Gout -revisited Shrenik Shah definition Monosodium urate (MSU) crystal deposition episodic and later persistent joint inflammation and tophi All MSU crystal deposition- broader definition EULAR- European
More informationGout: Develop treatment plan in William Jones, MS, RPh
Gout: Develop treatment plan in 2013 William Jones, MS, RPh (wnjones49@cox.net) Objectives Describe acute gouty arthritis Tx Describe Tx of chronic gouty arthritis. Define the target serum uric acid concentration
More informationHypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg
Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic
More informationUpdate on Gout for GPs
Update on Gout for GPs Dr Patrick Kiely PhD FRCP Consultant Physician and Rheumatologist St George s, London 2/3 1/3 Gut bacteria have uricase Chronic erosive arthropathy Clinical spectrum Making the diagnosis
More information1. To review the diagnosis of gout and its differential. 2. To understand the four stages of gout
Objectives 1. To review the diagnosis of gout and its differential GOUT 2. To understand the four stages of gout 3. To develop an approach for the acute treatment of gout Anthony Lim 9/13/12 Cycle 3 4.
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other PEGLOTICASE KRYSTEXXA 37154 GUIDELINES FOR USE 1. Does the patient have a diagnosis of symptomatic chronic gout (prior to initiating Krystexxa therapy) with clinical
More informationAchieving Gout Goals in Your Practice An Interview with Paul P. Doghramji, MD, FAAFP
Achieving Gout Goals in Your Practice An Interview with Paul P. Doghramji, MD, FAAFP Dr. Paul Doghramji is attending physician at the Pottstown Memorial Medical Center and medical director of Health Services
More informationProfessional organisation statement template
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence
More informationNew Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD
New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines
More informationMore Than A Pain In The Big Toe
More Than A Pain In The Big Toe Organisation Name: Counties Manukau Health Presenter(s): Rebecca Lawn HRT 1520 Innovations Workshops and Awards 19-20 November 2015, Sydney Key Problem There are more than
More informationA new model for prescribing varenicline
Pharmacist Independent Prescribers in partnership with A new model for prescribing varenicline Dear Stop Smoking Advisor You will be aware of the stop smoking drug varenicline that goes under the brand
More informationACP Rheumatology Pearls. Adam Q Carlson MD Assistant Professor UVA Rheumatology
ACP Rheumatology Pearls Adam Q Carlson MD Assistant Professor UVA Rheumatology Disclosures I have no personal or professional disclosures Case #1 27 yo woman with a history of systemic lupus complicated
More informationRole of the Clinical Pharmacist in Primary Care
Role of the Clinical Pharmacist in Primary Care Amy Kramer, Pharm.D., Manager Clinical Pharmacy Services Kaiser Permanente Holly Miller, Pharm.D., BCACP, Primary Care Clinical Pharmacist Kaiser Permanente
More informationEffectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study
Research Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study Robert D Goldfien, 1 Michele S Ng, 2 Goldie Yip, 2 Alice Hwe, 2
More informationEffectiveness of a pharmacist-based gout care management program in a large integrated health plan: Results from a pilot study For peer review only
BMJ Open Effectiveness of a pharmacist-based gout care management program in a large integrated health plan: Results from a pilot study Journal: BMJ Open Manuscript ID: bmjopen--00 Article Type: Research
More informationSTANDARD treatment algorithm mmHg
STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If
More informationIntegrated Care Pathway (ICP) for the. Management of clozapine INPATIENT INITIATION
Document Reference MM 048 Integrated Care Pathway (ICP) for the Management of clozapine INPATIENT INITIATION Surname Title Address Forenames Date of Birth RT/NHS number Care Co-ordinator GP CS number Consultant
More informationA Patient s Guide to Gout. Foot and Ankle Center of Massachusetts, P.C.
A Patient s Guide to Gout Welcome to Foot and Ankle Center of Massachusetts, where we believe in accelerating your learning curve with educational materials that are clearly written and professionally
More informationColin Edwards. Cardiologist Auckland Heart Group Waitemata Health
Colin Edwards Cardiologist Auckland Heart Group Waitemata Health AUG 2012 Introduction Case Summary BP MEASUREMENTS measured seated mean of 2 BP recordings per visit at least 2 visits Diet Exercise Weight
More informationRheumatologic Emergencies It s not just swollen joints. Joanne Homik Rheumatologist University of Alberta
Rheumatologic Emergencies It s not just swollen joints Joanne Homik Rheumatologist University of Alberta Or is it? Disclosures No relevant conflicts of interest regarding the content of this presentation
More informationEssence of the Revised Guideline for the Management of Hyperuricemia and Gout
Research and Reviews Essence of the Revised Guideline for the Management of Hyperuricemia and Gout JMAJ 55(4): 324 329, 2012 Hisashi YAMANAKA,* 1 The Guideline Revising Committee of Japanese Society of
More informationUrate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout
Philippine Journal of Internal Medicine Meta-Analysis Urate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout Erika Bianca S. Villazor-Isidro, M.D.*; John Carlo G.
More informationCase presentation. serum uric acid = 11.5 mg/dl 24-hour uric acid excretion = 300 mg
GOUT 55 y/o male 12 hours pain in my big toe & ankle went to bed last night feeling fine felt as if had broken toe this morning similar problems in right ankle & left wrist Case presentation lab studies
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationFebuxostat now subsidised on Special Authority
Gout update: Febuxostat now subsidised on Special Authority 38 Febuxostat was added to the New Zealand Pharmaceutical Schedule on 1 June, 2014. It is now available as a third-line preventive treatment
More informationHypertension and the Challenge of Adherence. Geneva Clark Briggs, Pharm.D., BCPS
Hypertension and the Challenge of Adherence Geneva Clark Briggs, Pharm.D., BCPS Outline Brief overview of HTN and pharmacologic therapies Role of pharmacists in collaboration with patients and physicians
More informationLong-term Treatment of Gout: New Opportunities for Improved Outcomes
Long-term Treatment of Gout: New Opportunities for Improved Outcomes Paul P. Doghramji, MD, FAAFP CONTINUING MEDICAL EDUCATION LEARNING OBJECTIVES Make a presumptive diagnosis of gout based on history
More informationGout Hanan Abdel Rehim
Review article 35 Gout Hanan Abdel Rehim Department of Internal Medicine, Kasr-Al Aini School of Medicine, Cairo University, Cairo, Egypt Correspondence to Hanan Abdel Rehim, MD, 11 Ismaiel Wahby Street,
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationAPPENDIX 2F Management of Cholesterol
Patients with established CVD: Coronary heart disease Cerebrovascular disease Peripheral vascular disease APPEDIX 2F Management of Cholesterol Patients at high risk of cardiovascular events: Chronic kidney
More informationRheumatology Subcommittee of PTAC Meeting held 7 October (minutes for web publishing)
Rheumatology Subcommittee of PTAC Meeting held 7 October 2014 (minutes for web publishing) Rheumatology Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationUric acid and CKD. Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George
Uric acid and CKD Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George Hospital @Badves Case Mr J, 52 Male, referred in June 2015 DM type 2 (4 years), HTN, diabetic retinopathy, diabetic
More informationGout: Let s Be Crystal Clear. Dr. Philip A. Baer Seacourses Asia CME December 2017
Gout: Let s Be Crystal Clear Dr. Philip A. Baer Seacourses Asia CME December 2017 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or
More informationGout Goals Are Not Being Achieved!! Strengthening The Provider/Patient Alliance Featuring PEPtools TM JointsAflame
Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance QS Priorities Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance Paul P. Doghramji, MD, FAAFP
More informationNew Drug Evaluation: lesinurad tablet, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationMonitoring polypharmacy and reducing problematic prescribing
CLINICAL AUDIT Monitoring polypharmacy and reducing problematic prescribing Valid to November 2020 bpac nz better medicin e Audit Focus Patients taking ten or more medicines are at an increased risk of
More informationCost-effectiveness of lesinurad (Zurampic ) for the treatment of adult patients with gout
Cost-effectiveness of lesinurad (Zurampic ) for the treatment of adult patients with gout The NCPE has issued a recommendation regarding the cost-effectiveness of Lesinurad (Zurampic ) in combination with
More informationTitle: Chronic Kidney Disease in Gout in a Managed Care Setting
Author's response to reviews Title: Chronic Kidney Disease in Gout in a Managed Care Setting Authors: Mahesh J Fuldeore (mahesh.fuldeore@abbott.com) Aylin A Riedel (aylin.reidel@i3innovus.com) Victoria
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationManaging Gout A Review of the Research for Adults
Managing Gout A Review of the Research for Adults e Is This Information Right for Me? This information is right for you if: Your health care professional* has said that you have gout. You are age 18 or
More informationMicrocrystal Arthritis: From Gout To Osteoarthritis Vilnius, Lithuania,
Microcrystal Arthritis: From Gout To Osteoarthritis Vilnius, Lithuania, 22.9.2017 Prof Alexander So Service of Rheumatology CHUV and UNIL, Lausanne, Switzerland 2 Happy anniversary 3 4 Disclosures Consultant:
More informationPatients Will Be Safe With A-L-L Heart Protection. Care Management Institute Kaiser Permanente 9/2012
Patients Will Be Safe With A-L-L Heart Protection Jim.R.Dudl@kp.org Care Management Institute Kaiser Permanente 9/2012 Lets Discuss.. How A-L-L evolved: What was the problem? did modeling predict? happened?
More informationTo Take or Not To Take?
To Take or Not To Take? Assessment Question How do the terms adherence & compliance differ? 1. The terms are synonymous 2.Adherence assumes collaboration between patient & provider while compliance suggests
More informationManaaki Hauora-Supporting Wellness Learning Session 3 Tuesday 10 November Owning My Gout (OMG)
Manaaki Hauora-Supporting Wellness Learning Session 3 Tuesday 10 November 2015 Owning My Gout (OMG) Aim 90% of eligible patients with gout at The Doctors, Ti Rakau* will be enabled to self manage their
More informationInterventions to reduce progression of CKD what is the evidence? John Feehally
Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think
More informationTeresa Neal. Pippa Travers-Mason. Aboriginal Health Worker. Consultant clinical pharmacist MPH, Med, BPharm AACPA
Teresa Neal Aboriginal Health Worker Pippa Travers-Mason Consultant clinical pharmacist MPH, Med, BPharm AACPA WHERE Burden of disease So what do we do stats To date: Started October 2012 770 ish reviews
More informationSchool of Health and Related Research (ScHARR), The University of Sheffield. Produced by
Pegloticase for the treatment of hyperuricaemia in people with symptomatic gout whose disease is refractory to conventional uratelowering therapy, or in whom conventional urate-lowering therapy is contraindicated
More informationMPharmProgramme. Hypertension (HTN)
MPharmProgramme Hypertension (HTN) Slide 1 of 30 Overview Definition Prevalence Type Causes Diagnosis Management Patients perspective Slide 2 of 30 Definition It is not a disease! So what is it? What two
More informationNew Drug Evaluation: lesinurad tablet, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationTEAMcare at The Polyclinic: Collaborative Care for Diabetes and Depression
TEAMcare at The Polyclinic: Collaborative Care for Diabetes and Depression Michael J. Tronolone, MD, MMM CMO, The Polyclinic Seattle, WA April 3, 2014 1 The Multi-Condition Patient JAMA, April 7, 2010
More informationFirst Presentation of Joint Pain
First Presentation of Joint Pain Andrew Harrison Rheumatologist Wellington Regional Rheumatology Unit, HVDHB Bowen Centre, Crofton Downs, Wellington Assoc. Prof. in Medicine, University of Otago Wellington
More informationGout Goals Are Not Being Achieved!! Strengthening The Provider/Patient Alliance Featuring PEPtools JointsAflame
Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance QS Priorities Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance Featuring PEPtools TM JointsAflame
More informationChronic gout: Barriers to effective management
Chronic gout: Barriers to effective management Sylvie Rogenmoser, Mark H Arnold Background Gout is one of the most common inflammatory arthropathies, and the pathogenesis is well understood. In Australia,
More informationHypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016
Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Hypertension Update Vincent J. Canzanello, M.D. Consultant, Division of Nephrology and Hypertension Professor or Medicine College
More informationGout Goals Are Not Being Achieved!! Strengthening The Provider/Patient Alliance Featuring PEPtools JointsAflame
Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance QS Priorities Gout Goals Are ot Being Achieved!! Strengthening The Provider/Patient Alliance Featuring PEPtools TM JointsAflame
More informationTherapy for Gout: The Past
Advances in Therapy for Gout: 2011 The Past, Present, and Future Therapy for Gout: The Past May 22, 1997 Pity a Tyrannosaur? Sue Had Gout By MALCOLM W. BROWNE Jonathan Graf, M.D. Associate Professor of
More informationLecture 8 Gout Hinch. Pathogenesis of acute attacks
Gout: disease characterized by deposition of monosodium crystals in soft tissues (cartilage, tendons, bursa) recurrent episodes of acute joint pain & inflammation Pathogenesis of acute attacks Epidemiology:
More informationWhat a Rheumatologists needs to know about Nephrology. Dr Louise Moist University of Western Ontario
What a Rheumatologists needs to know about Nephrology Dr Louise Moist University of Western Ontario Louise/moist@lhsc.on.ca May 2014 Disclosures Advisory board Amgen, Leo Pharma, Roche Learning Objectives
More informationRetreatment with Pegloticase after a Gap in Therapy in Patients with Gout: A Report of Four Cases
Rheumatol Ther (2018) 5:583 594 https://doi.org/10.1007/s40744-018-0111-9 CASE SERIES Retreatment with Pegloticase after a Gap in Therapy in Patients with Gout: A Report of Four Cases Allan H. Morton.
More information(minutes for web publishing)
Rheumatology Subcommittee of the Pharmacology and Therapeutics Advisory Committee (PTAC) Meeting held on 17 October 2017 (minutes for web publishing) Rheumatology Subcommittee minutes are published in
More informationAd-Hoc Rheumatology Subcommittee of PTAC meeting held 8 March. (minutes for web publishing)
Ad-Hoc Rheumatology Subcommittee of PTAC meeting held 8 March 2011 (minutes for web publishing) Ad-Hoc Rheumatology Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationProduct Cost per Pack Cost per 28 days (assuming 2 sprays od) Flixonase years 50mcg in both nostrils od (increasing to max bd prn)
Protocol for Flixonase to Avamys Nasal Spray Switch May 2010 1. Reason Avamys contains the corticosteroid fluticasone furoate (27.5mcg/spray) and Flixonase nasal spray contains fluticasone propionate (50mcg/spray).
More informationHelpline No:
ARTHRITIS FOUNDATION Registered Nonprofit Organisation - No. 002-847 NPO Helpline No: 0861 30 30 30 DRUGS AND ARTHRITIS This information leaflet is published by the Arthritis Foundation as part of our
More informationMRCP(UK) PACES. INFORMATION FOR THE CANDIDATE Training Scenario N 003 SAMPLE HOST CENTRE Station 5: BRIEF CLINICAL CONSULTATION
INFORMATION FOR THE CANDIDATE MRCP(UK) PACES Station 5: BRIEF CLINICAL CONSULTATION Patient details: Mr JS aged 70. Your role: You are the doctor in the medical assessment unit. You have 10 minutes with
More informationDiabetes Passport. East Coast Area Diabetes Integrated Care
Diabetes Passport East Coast Area Diabetes Integrated Care Personal Details Name: Address: Developed by East Coast Area Diabetes Programme (ECAD), 2014. Thanks to Beaumont Hospital for allowing us to use
More informationThroat swabs and antibiotic use for GAS sore throat. Sandy Dawson
Throat swabs and antibiotic use for GAS sore throat Sandy Dawson Background Acute rheumatic fever (ARF) and consequent rheumatic heart disease (RHD) remain a significant cause of morbidity and premature
More information5.2 Key priorities for implementation
5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail
More informationHypertension AN OVERVIEW
AN OVERVIEW Hypertension Your doctor has determined that you have high blood pressure, or hypertension. Although high blood pressure is never really cured, it can be controlled by early detection, lifestyle
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Krystexxa) Reference Number: CP.CPA.57 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationFructose, Uric Acid and Hypertension in Children and Adolescents
Fructose, Uric Acid and Hypertension in Children and Adolescents Daniel I. Feig, MD, PhD, MS Director, Division of Nephrology Department of Pediatrics University of Alabama, Birmingham Topics for Discussion
More informationChapter Two Renal function measures in the adolescent NHANES population
0 Chapter Two Renal function measures in the adolescent NHANES population In youth acquire that which may restore the damage of old age; and if you are mindful that old age has wisdom for its food, you
More informationEnhanced Primary Care Pathway: Gout
Enhanced Primary Care Pathway: Gout 1. Focused summary of gout relevant to primary care Significance: Gout is a chronic, progressive, inflammatory disease requiring appropriate long-term management. Gout
More informationHave you seen a patient like Elaine *?
(linagliptin) 5mg tablets Have you seen a patient like Elaine *? *Hypothetical patient profile Elaine * : 60 years old Housewife *Hypothetical patient profile ELAINE*: T2D Patient with early signs of kidney
More informationGout. Clinical features Most commonly affects middle-aged males. It is an acute and usually relapsing selflimiting
Gout Gout is a syndrome caused by an inflammatory response to the formation of monosodium urate monohydrate crystals which develop secondary to hyperuricemia. Acute and chronic forms are recognized. Hyperuricemia
More informationType 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
More informationCase Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic
Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for
More informationPharmacological Management of Knee Pain
Pharmacological Management of Knee Pain Dr Indi Rasaratnam Consultant Rheumatologist, Epworth Health Care & The Alfred Senior Lecturer, Department of Medicine, Monash University Outline of Presentation
More informationSolomon Islands guidelines. for the management of major non-communicable diseases (NCDs) in primary health care
Solomon Islands guidelines for the management of major non-communicable diseases (NCDs) in primary health care Contents Foreword Introduction 1. Cardiovascular risk assessment and diabetes screening 1
More informationChronic Kidney Disease due to Diabetes (Diabetic Nephropathy)
Chronic Kidney Disease due to Diabetes (Diabetic Nephropathy) Patient information Oxford Kidney Unit If you have been told you have chronic kidney disease (CKD) due to diabetic nephropathy this leaflet
More informationSubject: Krystexxa (pegloticase) Original Effective Date: 06/26/13. Policy Number: MCP-138. Revision Date(s):
Subject: Krystexxa (pegloticase) Original Effective Date: 06/26/13 Policy Number: MCP-138 Revision Date(s): Review Date(s): 12/16/15; 6/15/2016; 3/21/2017 DISCLAIMER This Molina Clinical Policy (MCP) is
More informationPennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016
Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016 Disclosures: Gout and Pseudogout Wayne Blount MD Speaker has no disclosures
More information2) An 87 year old female who is 2 weeks post TKR presents with a sore swollen knee. She has a history of atrial fibrillation. Her vital signs are:
EMQ - Rheumatology For each clinical vignette match the correct diagnosis. Reiter s syndrome Pseudogout Septic arthritis Gout Haemarthrosis Traumatic effusion Ankylosing spondylitis Rheumatoid arthritis
More informationClinical Inertia. The Promise of Collaborative Care for Treating Behavioral Health and Chronic Medical Conditions. Study: 161,697 Patients 4/12/17
The Promise of Collaborative Care for Treating Behavioral Health and Chronic Medical Conditions Paul Ciechanowski, MD, MPH Clinical Associate Professor, University of Washington Chief Medical Officer,
More informationClinical Study Allopurinol, Benzbromarone, or a Combination in Treating Patients with Gout: Analysis of a Series of Outpatients
Hindawi Publishing Corporation International Journal of Rheumatology Volume 2014, Article ID 263720, 5 pages http://dx.doi.org/10.1155/2014/263720 Clinical Study Allopurinol, Benzbromarone, or a Combination
More informationKanyini Guidelines Adherence with the Polypill (Kanyini GAP)
Kanyini Guidelines Adherence with the Polypill (Kanyini GAP) Disclosures Funded by the National Health and Medical Research Council of Australia. Dr Reddy s Laboratories Ltd manufactured and supplied polypills
More informationAllopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease
Allopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease Michelle P Kao, Donald S Ang, Steve Gandy, Chim C Lang, Allan D Struthers Division of
More information